Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 07 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Oxygenta Pharmaceutical Limited, a micro-cap pharmaceutical company with a market capitalisation of ₹187.00 crores, reported its Q1 FY27 results with a dramatic revenue surge that failed to translate into profitability. The company posted a net loss of ₹2.10 crores for the quarter ended June 2026, representing a marginal improvement from the ₹1.70 crore loss in Q4 FY26 but a significant deterioration from the ₹6.11 crore loss in Q1 FY25. Despite net sales surging 144.55% year-on-year to ₹37.00 crores, the company remains trapped in a loss-making spiral that has persisted across multiple quarters, raising serious questions about operational viability and the sustainability of its business model.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 05 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 June 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 June 2026, providing investors with the latest insights into its performance and outlook.

Oxygenta Pharmaceutical Ltd’s share price declined sharply to hit a new 52-week low of Rs.43 on 11 June 2026, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock underperformed its sector and has been on a downward trajectory over the past three days, reflecting ongoing concerns about its financial health and valuation.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 19 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Oxygenta Pharmaceutical Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 April 2026, providing investors with the latest insights into the company’s performance and outlook.